<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085341</url>
  </required_header>
  <id_info>
    <org_study_id>GBV-102-003</org_study_id>
    <nct_id>NCT04085341</nct_id>
  </id_info>
  <brief_title>A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion</brief_title>
  <official_title>A Phase 2a Multicenter Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Sunitinib Malate Depot Formulation (GB-102) in Subjects With Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Graybug Vision</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Graybug Vision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2a multicenter, open-label, parallel-arm design study to evaluate the safety,
      tolerability and pharmacodynamics of a single intravitreal injection comparing 2 dose levels
      of GB-102 on subjects with Diabetic Macular Edema and Retinal Vein Occlusion
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2a multicenter, open-label, parallel-arm design study to evaluate the safety,
      tolerability and pharmacodynamics of a single intravitreal injection comparing 2 dose levels
      (1 mg and 2 mg) of GB-102 on subjects with Diabetic Macular Edema and Retinal Vein Occlusion
      who have received prior treatment with anti-vascular endothelial growth factor (VEGF)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2019</start_date>
  <completion_date type="Actual">June 5, 2020</completion_date>
  <primary_completion_date type="Actual">June 5, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel-arm design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open-label study design</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of ocular and non-ocular adverse events (AEs) and serious adverse events at all study visits</measure>
    <time_frame>Baseline through Month 6</time_frame>
    <description>Number of adverse events in total and number of subjects with an adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in BCVA (ETDRS) at all study visits</measure>
    <time_frame>Baseline through Month 6</time_frame>
    <description>BCVA = best corrected visual acuity; ETDRS = early treatment of diabetic retinopathy
BCVA = 0 (worst) to 100 (best)
Assessment of change in BCVA (ETDRS letter score) from baseline at all visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in CST (SD-OCT) at all study visits</measure>
    <time_frame>Baseline through Month 6</time_frame>
    <description>CST = central subfield thickness
SD-OCT = spectral domain-optical coherence tomography
Assessment of change in CST (μm) measurement from baseline at all visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to rescue treatment</measure>
    <time_frame>Baseline through Month 6</time_frame>
    <description>Assessment of time to rescue treatment over 6 months of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Retina Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>GB-102 Dose 1 (1 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravitreal (IVT) GB-102 (1 mg) in the study eye at Baseline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB-102 Dose 2 (2 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravitreal (IVT) GB-102 (2 mg) in the study eye at Baseline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GB-102</intervention_name>
    <description>Intravitreal injection of GB-102</description>
    <arm_group_label>GB-102 Dose 1 (1 mg)</arm_group_label>
    <arm_group_label>GB-102 Dose 2 (2 mg)</arm_group_label>
    <other_name>Sunitinib malate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females ≥ 21 years of age

          -  Known diagnosis of macular edema secondary to diabetic macular edema or retinal vein
             occlusion treated with at least 3 prior IVT injections of an anti-VEGF agent
             (aflibercept, bevacizumab, or ranibizumab)

          -  Demonstrated response to prior anti-VEGF treatment since diagnosis

          -  BCVA of 31 letters or better

        Exclusion Criteria:

          -  History, within 6 months prior to screening, of any of the following: myocardial
             infarction, any cardiac event requiring hospitalization, treatment for acute
             congestive heart failure, transient ischemic attack, or stroke

          -  Uncontrolled hypertension, diabetes mellitus or IOP

          -  Chronic renal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Graybug Vision, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retinal Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Retina</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Care Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Retina</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02482</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texoma Retina Center</name>
      <address>
        <city>Denison</city>
        <state>Texas</state>
        <zip>75020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular Edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

